# A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation

> **NCT02659735** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 90 (actual)

## Conditions studied

- Influenza A Virus

## Interventions

- **DRUG:** JNJ-63623872 300 milligram (mg)
- **DRUG:** JNJ-63623872 600 mg
- **DRUG:** JNJ-63623872 600 mg
- **DRUG:** JNJ-63623872 600 mg

## Key facts

- **NCT ID:** NCT02659735
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659735, "A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02659735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*